Cargando…
High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer
BACKGROUND: Not merely the onset of immune evasion, but other factors, such as acidosis and fibrosis, are also major barriers in cancer therapeutics. Dense fibrosis is a hallmark of pancreatic ductal carcinoma (PDAC), in which hyperactivation of focal adhesion kinase (FAK) in tumor cells was shown t...
Autores principales: | Tsutaho, Akio, Hashimoto, Ari, Hashimoto, Shigeru, Hata, Soichiro, Kachi, Shion, Hirano, Satoshi, Sabe, Hisataka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313132/ https://www.ncbi.nlm.nih.gov/pubmed/32580737 http://dx.doi.org/10.1186/s12964-020-00608-8 |
Ejemplares similares
-
Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer
por: Hashimoto, Ari, et al.
Publicado: (2021) -
ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer
por: Hashimoto, Shigeru, et al.
Publicado: (2019) -
Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model
por: Otsuka, Yutaro, et al.
Publicado: (2018) -
The EGFR-GEP100-Arf6-AMAP1 Signaling Pathway Specific to Breast Cancer Invasion and Metastasis(†)
por: Sabe, Hisataka, et al.
Publicado: (2009) -
GEP100-Arf6-AMAP1-Cortactin Pathway Frequently Used in Cancer Invasion Is Activated by VEGFR2 to Promote Angiogenesis
por: Hashimoto, Ari, et al.
Publicado: (2011)